News

Cherish, the study assessing Spinraza in later-onset SMA, found that children receiving the drug experienced a highly statistically-significant improvement in motor function compared to those who did not

The company will buy nearly seven million newly issued Aimmune’s common stock shares each priced at $19.20. Both Aimmune and Nestlé Health Science have also agreed to collaborate on

Livatag (doxorubicine Transdrug, a nanoparticle formulation of doxorubicin) is currently being evaluated clinically as a monotherapy in a Phase III ReLive trial for second-line advanced hepatocellular carcinoma (HCC). More

PARP is a naturally-occurring enzyme in the body that repairs damage to DNA in cells. While this repair is a useful process to maintain the integrity of healthy

NeoGAA is a second-generation enzyme replacement therapy being studied for the treatment of Pompe disease. Pompe disease is a progressive, debilitating and often fatal neuromuscular disease caused by

The approval of the company’s supplemental Biologics License Application makes it the first and only systemic therapy to treat pediatric patients aged 4 to 17 affected by the

In connection with the acquisition, EnBiotix has established EnBiotix. EnBiotix has also initiated a collaboration with Leipzig University and AMPT’s scientific co-founder, Professor Ralf Hoffmann, Ph.D. EnBiotix chairman

BCT-197 is currently in a Phase 2 study for the treatment of acute exacerbations of COPD (AECOPD). This study evaluated potential drug interactions between acumapimod and the antibiotic

The insulin glargine, which has been co-developed by Mylan and Biocon, is used to treat adults with Type 2 diabetes and adults and paediatric patients with type 1